Merck's Frazier bets on science over short-term gains

Merck ($MRK) CEO Kenneth Frazier has taken his share of flak from Wall Street about the U.S. drug giant's spending plans. Frazier went to bat for his company's big $8 billion R&D budget this week, pointing out that in the history of the pharma biz the groups that stay on the leading edge of science come out on top. This is clearly a long-term proposition, as Merck's stock performance has lagged that of R&D-cutback-happy Pfizer ($PFE). Report

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.